The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 31, 2023
Filed:
May. 30, 2018
Applicant:
Innovative Cellular Therapeutics Holdings, Ltd., Rockville, MD (US);
Inventors:
Lei Xiao, Rockville, MD (US);
Chengfei Pu, Shanghai, CN;
Zhiyuan Cao, Shanghai, CN;
Zhao Wu, Shanghai, CN;
Assignee:
Innovative Cellular Therapeutics Holdings, Ltd., Rockville, MD (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/0783 (2010.01); C12N 15/63 (2006.01); A61K 35/17 (2015.01); C07K 14/725 (2006.01); C07K 14/705 (2006.01); A61P 35/00 (2006.01); A61K 39/395 (2006.01); C07K 14/075 (2006.01); A61K 48/00 (2006.01); C07K 14/525 (2006.01); C07K 14/71 (2006.01); C07K 16/30 (2006.01); C12N 15/85 (2006.01); A61K 39/00 (2006.01); C12N 9/12 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0638 (2013.01); A61K 35/17 (2013.01); A61K 39/0011 (2013.01); A61K 39/39558 (2013.01); A61K 48/005 (2013.01); A61P 35/00 (2018.01); C07K 14/075 (2013.01); C07K 14/525 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/71 (2013.01); C07K 16/2803 (2013.01); C07K 16/30 (2013.01); C12N 5/0636 (2013.01); C12N 5/0646 (2013.01); C12N 9/1276 (2013.01); C12N 15/85 (2013.01); C12Y 207/07049 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/585 (2013.01); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/80 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); C12N 2510/00 (2013.01); C12N 2740/16043 (2013.01);
Abstract
Embodiments described herein relate to compositions including genetically modified CAR cells and uses thereof for treating cancer. Some embodiments of the present disclosure relate to compositions and methods for T cell response enhancement and/or CAR cell preparation. For example, a method may include obtaining cells comprising a CAR and culturing the cells in the presence of an agent that is recognized by the extracellular domain of the CAR.